A Phase I Dose Escalation Trial of the Humanized Anti-CD47 Monoclonal Antibody Hu5F9-G4 in Haematological Malignancies (CAMELLIA)

Trial Profile

A Phase I Dose Escalation Trial of the Humanized Anti-CD47 Monoclonal Antibody Hu5F9-G4 in Haematological Malignancies (CAMELLIA)

Active, no longer recruiting
Phase of Trial: Phase I

Latest Information Update: 17 Aug 2017

At a glance

  • Drugs Hu5F9 G4 (Primary)
  • Indications Acute myeloid leukaemia; Myelodysplastic syndromes
  • Focus Adverse reactions
  • Acronyms CAMELLIA
  • Most Recent Events

    • 10 Aug 2017 Planned number of patients changed from 30 to 40.
    • 10 Aug 2017 Planned End Date changed to 1 Aug 2018.
    • 10 Aug 2017 Planned primary completion date changed from 1 Mar 2017 to 1 Mar 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top